A stem cell and tissue engineering therapy has been EU approved to treat patients with a rare, but devastating, eye condition called limbal stem cell deficiency (LSCD). This disorder stems from scar tissue formation, and often causes pain, which in turn leads to vision impairment and often blindness. LSCD can arise from chemical burns to the eye, which often occurs with people in the military and other dangerous lines of work. Since this disorder is rare, the treatment options are more limited than they would be for more commonplace conditions. Current conventional treatments involve placating the symptoms, accompanied by painful procedures to remove the scarring of corneal tissue in the eye, but until now, no effective cure has been available.
The groundbreaking therapy involves obtaining the patient’s own (autologous) stem cells and using a novel culturing protocol to differentiate the cells into healthy tissue that will replace the scar tissue covering the eye. The approved approach, recovering the patient’s own stem cells and applying advanced culturing protocols – is being applied to other regenerative therapies to expand treatments options for a broad range of disease, trauma and injury.
As the treatment demonstrates, the best stem cells to use in emerging regenerative therapies will be the patient’s own [autologous stem cells] as this negates the need to find a suitable donor and eliminates the chances of rejection of the transplanted tissue. To learn how to bank your own valuable stem cells to insure your future health, visit www.StemSave.com or call 877-783-6728 (877-StemSave) today.
The Future of Regenerative Medicine is Now™
To view the full article, click here.